WO2004046170A3 - Tubulysine, herstellungsverfahren und tubulysin-mittel - Google Patents

Tubulysine, herstellungsverfahren und tubulysin-mittel Download PDF

Info

Publication number
WO2004046170A3
WO2004046170A3 PCT/EP2003/011603 EP0311603W WO2004046170A3 WO 2004046170 A3 WO2004046170 A3 WO 2004046170A3 EP 0311603 W EP0311603 W EP 0311603W WO 2004046170 A3 WO2004046170 A3 WO 2004046170A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
alkenyl
tubulysin
tubulysins
Prior art date
Application number
PCT/EP2003/011603
Other languages
English (en)
French (fr)
Other versions
WO2004046170A2 (de
Inventor
Gerhard Hoefle
Nicole Glaser
Heinrich Steinmetz
Thomas Leibold
Florenz Sasse
Original Assignee
Biotechnolog Forschung Gmbh
Gerhard Hoefle
Nicole Glaser
Heinrich Steinmetz
Thomas Leibold
Florenz Sasse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotechnolog Forschung Gmbh, Gerhard Hoefle, Nicole Glaser, Heinrich Steinmetz, Thomas Leibold, Florenz Sasse filed Critical Biotechnolog Forschung Gmbh
Priority to EP03775204A priority Critical patent/EP1562979B1/de
Priority to AU2003283282A priority patent/AU2003283282A1/en
Priority to US10/535,630 priority patent/US7754885B2/en
Priority to DE50310721T priority patent/DE50310721D1/de
Priority to JP2004552485A priority patent/JP4620467B2/ja
Publication of WO2004046170A2 publication Critical patent/WO2004046170A2/de
Publication of WO2004046170A3 publication Critical patent/WO2004046170A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft eine Verbindung der folgenden allgemeinen Formel (Tubulysin) mit den folgenden Bedeutungen für R, R1, R2, R3, R4, R5, R6, R7,R8 R9, R10, R11, S, T, U, V, W, X, Y und Z: R = H, C1-4-Alkyl, Aryl, OR1, NR1R2 oder NH- (CH2) 2-R1 = H, C1-6-Alkyl oder Aryl R2 = H, C1-6-Alkyl oder Aryl S = H, Hal, NO2 oder NHR3 U = H, Hal, NO2 oder NHR3 R3 = H, HCO oder C1-4-Alkyl-CO T = H oder OR4 R4 = H, C1-4-Alkyl, Aryl, COR5, P (O) (OR6) 2 oder SO3R6 R5 = C1-6-Alkyl, Alkenyl, Aryl oder Heteroaryl R6 = H, C1-4-Alkyl oder Metallion V = H oder R7 oder (für W = O) O R7 = H, C1-4-Alkyl oder COR8 R8 = C-1-4-Alkyl, Alkenyl oder Aryl W = H oder C1-4-Alkyl oder (für V = O) O X = H, C1-4-Alkyl, Alkenyl oder CH20R9 R9 = H, C1-4-Alkyl, Alkenyl, Aryl oder COR10 R10 = C1-6-Alkyl, Alkenyl, Aryl oder Heteroaryl Y = (für Z = CH3 oder COR11)freies Elektronenpaar oder (für Z =CH3) O R11 = C1-4-Alkyl, CF3 oder Aryl und/oder Z = (für Y = O oder freies Elektronenpaar) CH3 oder (für Y = freies Elektronenpaar) COR11.
PCT/EP2003/011603 2002-11-21 2003-10-20 Tubulysine, herstellungsverfahren und tubulysin-mittel WO2004046170A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03775204A EP1562979B1 (de) 2002-11-21 2003-10-20 Tubulysine, herstellungsverfahren und tubulysin-mittel
AU2003283282A AU2003283282A1 (en) 2002-11-21 2003-10-20 Tubulysins, method for producing the same and tubulysin preparations
US10/535,630 US7754885B2 (en) 2002-11-21 2003-10-20 Tubulysins, method for producing the same and tubulysin preparations
DE50310721T DE50310721D1 (de) 2002-11-21 2003-10-20 Tubulysine, herstellungsverfahren und tubulysin-mittel
JP2004552485A JP4620467B2 (ja) 2002-11-21 2003-10-20 チューブライシン、その製造方法、及び、チューブライシン製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10254439.5 2002-11-21
DE10254439A DE10254439A1 (de) 2002-11-21 2002-11-21 Tubulysine, Herstellungsverfahren und Tubulysin-Mittel

Publications (2)

Publication Number Publication Date
WO2004046170A2 WO2004046170A2 (de) 2004-06-03
WO2004046170A3 true WO2004046170A3 (de) 2004-07-01

Family

ID=32240267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011603 WO2004046170A2 (de) 2002-11-21 2003-10-20 Tubulysine, herstellungsverfahren und tubulysin-mittel

Country Status (7)

Country Link
US (1) US7754885B2 (de)
EP (2) EP2028185A1 (de)
JP (1) JP4620467B2 (de)
AT (1) ATE412659T1 (de)
AU (1) AU2003283282A1 (de)
DE (2) DE10254439A1 (de)
WO (1) WO2004046170A2 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231868D1 (de) * 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
ES2324708T3 (es) * 2002-05-15 2009-08-13 Endocyte, Inc. Conjugados de vitamina-mitomicina.
EP1523493B1 (de) * 2002-07-09 2013-09-04 Dömling, Alexander Neue tubulysinanaloga
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
US8044200B2 (en) * 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
CA2617660C (en) * 2005-08-19 2014-03-25 Endocyte, Inc. Multi-drug ligand conjugates
EP2382995A3 (de) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligandenkonjugate von Vincaalkaloiden, Analoga und Derivaten
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
ES2463693T3 (es) * 2007-05-10 2014-05-29 R & D Biopharmaceuticals Gmbh Derivados de tubulisina
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009134279A1 (en) * 2007-07-20 2009-11-05 The Regents Of The University Of California Tubulysin d analogues
US20110263650A1 (en) * 2007-07-20 2011-10-27 Helmholtz-Zentrum Für Infektions-Forschung Gmbh Tubulysin D Analogues
EP2174947A1 (de) * 2008-09-25 2010-04-14 Universität des Saarlandes Bioaktive Prätubulysine und Verwendung davon
IT1394860B1 (it) * 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2409983A1 (de) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysinanaloga
EA025471B1 (ru) 2010-08-06 2016-12-30 Эндосайт, Инк. Способы получения тубулизинов
CN103747804B (zh) 2011-06-10 2016-08-17 梅尔莎纳医疗公司 蛋白质-聚合物-药物共轭物
IN2014CN04961A (de) * 2011-12-05 2015-09-18 Igenica Biotherapeutics Inc
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
CN107982545B (zh) 2012-05-15 2021-04-09 联宁（苏州）生物制药有限公司 药物偶联物，偶联方法，及其用途
HUE061182T2 (hu) 2012-07-12 2023-05-28 Hangzhou Dac Biotech Co Ltd Sejtkötõ molekulák konjugátumai citotoxikus szerekkel
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
EP2708243A1 (de) 2012-09-17 2014-03-19 OntoChem GmbH Rezeptor-Ligand-verbundene zytotoxische Moleküle
EP2908818A4 (de) 2012-10-16 2016-07-13 Endocyte Inc Wirkstofffreisetzungskonjugate mit unnatürlichen aminosäuren und verfahren zur verwendung
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EP2922818B1 (de) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophile binder und deren verwendung zur konjugation von wirkstoffen an zellbindende moleküle
EP2928504B1 (de) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Protein-polymer-wirkstoffkonjugate
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
WO2014126836A1 (en) 2013-02-14 2014-08-21 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
PL3057585T3 (pl) 2013-10-15 2020-12-28 Seagen Inc. Pegylowane elementy lek-łącznik do poprawy farmakokinetyki koniugatu ligand-lek
CA2940311C (en) 2014-01-28 2022-12-13 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
CN114262344A (zh) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
CN112826940A (zh) * 2014-11-11 2021-05-25 杭州多禧生物科技有限公司 细胞毒素分子同细胞结合受体分子的共轭体
US10590165B2 (en) 2015-01-28 2020-03-17 Sorrento Therapeutics, Inc. Antibody drug conjugates
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
ES2959663T3 (es) 2015-11-10 2024-02-27 Medimmune Llc Moléculas de unión específicas para ASCT2 y usos de las mismas
EP3383420B1 (de) 2015-12-04 2022-03-23 Seagen Inc. Konjugate von quaternierten tubulysinverbindungen
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3433278A4 (de) 2016-03-25 2019-11-06 Seattle Genetics, Inc. Verfahren zur herstellung von pegylierten wirkstoff-linkern und zwischenprodukten davon
KR102459469B1 (ko) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
MX2019010769A (es) 2017-03-24 2019-12-11 Seattle Genetics Inc Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
WO2019025983A1 (en) 2017-08-01 2019-02-07 Medimmune, Llc CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA
BR112021025984A2 (pt) 2019-06-29 2022-04-12 Hangzhou Dac Biotech Co Ltd Conjugado de anticorpo-derivado de tubulisina b (análogo), composto, composição farmacêutica, e, usos do conjugado, dos compostos e das composições farmacêuticas
WO2021013999A1 (en) 2019-07-24 2021-01-28 Ontochem Gmbh Receptor-targeting peptide-drug conjugates
MX2023002940A (es) 2020-09-11 2023-04-11 Medimmune Ltd Moleculas de union a b7-h4 terapeuticas.
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2024170660A1 (en) 2023-02-16 2024-08-22 Astrazeneca Ab Combination therapies for treatment of cancer with therapeutic binding molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19638870A1 (de) * 1996-09-23 1998-03-26 Biotechnolog Forschung Gmbh Verbindungen mit antimykotischer und cytostatischer Wirkung, Herstellungsverfahren, Mittel und DSM 11 092
DE10008089A1 (de) * 2000-02-22 2001-10-31 Biotechnolog Forschung Gmbh Syntheseverfahren zur Herstellung von Tubulysinen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1523493B1 (de) * 2002-07-09 2013-09-04 Dömling, Alexander Neue tubulysinanaloga
WO2008106080A2 (en) * 2007-02-27 2008-09-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of desacetoxytubulysin h and analogs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19638870A1 (de) * 1996-09-23 1998-03-26 Biotechnolog Forschung Gmbh Verbindungen mit antimykotischer und cytostatischer Wirkung, Herstellungsverfahren, Mittel und DSM 11 092
DE10008089A1 (de) * 2000-02-22 2001-10-31 Biotechnolog Forschung Gmbh Syntheseverfahren zur Herstellung von Tubulysinen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMEL E ET AL: "ANTIMITOTIC PEPTIDES AND DEPSIPEPTIDES", CURRENT MEDICINAL CHEMISTRY. ANTI-CANCER AGENTS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 2, no. 1, January 2002 (2002-01-01), pages 19 - 53, XP009021192, ISSN: 1568-0118 *
SASSE F ET AL: "TUBULYSINS, NEW CYTOSTATIC PEPTIDES FROM MYXOBACTERIA ACTING ON MICROTUBULI PRODUCTION, ISOLATION, PHYSICO-CHEMICAL AND BIOLOGICAL PROPERTIES", JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. TOKYO, JP, vol. 53, no. 9, September 2000 (2000-09-01), pages 879 - 885, XP009014740, ISSN: 0021-8820 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof

Also Published As

Publication number Publication date
ATE412659T1 (de) 2008-11-15
EP2028185A1 (de) 2009-02-25
DE10254439A1 (de) 2004-06-03
AU2003283282A8 (en) 2004-06-15
EP1562979A2 (de) 2005-08-17
US7754885B2 (en) 2010-07-13
AU2003283282A1 (en) 2004-06-15
JP2006518704A (ja) 2006-08-17
JP4620467B2 (ja) 2011-01-26
DE50310721D1 (de) 2008-12-11
US20060128754A1 (en) 2006-06-15
WO2004046170A2 (de) 2004-06-03
EP1562979B1 (de) 2008-10-29

Similar Documents

Publication Publication Date Title
WO2004046170A3 (de) Tubulysine, herstellungsverfahren und tubulysin-mittel
MY125006A (en) Permanent magnet including multiple ferromagnetic phases and method for producing the magnet
ITMI20011986A0 (it) Metodo e composizione per l'attivazione di cellule presentanti l'antigene
HUP0303428A2 (hu) Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
FI953140A (fi) Menetelmä organofiilisten metallioksidihiukkasten valmistamiseksi
AU2002366269A8 (en) Deposition method for nanostructure materials
AU2002366644A1 (en) Method for administering birb 796 bs
EP0840538A3 (de) In der Produktion schwerer Isotope gebrauchtes Target
BR0108777A (pt) Processo para preparar compostos de cianeto de multimetais, composto de cianeto de multimetais, uso do mesmo, e, processo para preparar álcoois de poliéter
WO2002062398A3 (en) Radioactively labelled conjugates of phosphonates
MY142270A (en) New process for the synthesis of (7-methoxy-1-naphthyl)acetonitrile and application in the synthesis of agomelatine
WO2003071660A3 (en) Linear motor with magnet rail support
DE69930702D1 (de) Shimanordnung für die Polfläche eines Magneten
AU2003210151A1 (en) Silicon-containing magnetic particles, method for producing said particles and use of the same
IL159534A0 (en) Method for the preparation of selectively-substituted corroles and new substituted corroles
DE60201016D1 (de) Verfahren zum herstellen eines körperpflegemittels
DE60102485D1 (de) Herstellung von aluminium-silizium-legierungen
ATE447420T1 (de) Hydrogelhaltiges kompositmaterial, hergestellt durch elektrisch-ausgelöste präzipitation einer festphase
FR2379145A1 (fr) Ensemble de bobines pour gyroscopes a resonance magnetique nucleaire
ITMI20020580A1 (it) Autoveicolo nonche' procedimento per il funzionamento di un autoveicolo
EP1529783A3 (de) Derivative von 9,10-Dihydro-9-oxa-10-phosphaphenanthren-10-oxid
DE59801474D1 (de) Verfahren zur herstellung eines magnetlegierungspulvers
WO2003027148A8 (en) Disulfide-reduced neogalactosyl serum albumin and use of radiolabeled derivative thereof for liver imaging
MXPA05008108A (es) Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos.
DE60214414D1 (de) Peptidderivat, pharmazeutisch unbedenkliches salz davon, verfahren zu dessen herstellung und dessen verwendung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003775204

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004552485

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003775204

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10535630

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2006128754

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10535630

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10535630

Country of ref document: US